EPRX
Eupraxia Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology · CA
$8.40
+12.00%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -45.8%
- EBIT
- -64.8%
- EPS
- -19.3%
- Free cash flow
- -18.4%
- Operating cash flow
- -17.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -57.5%
Three-year CAGR
- Revenue
- —
- EBITDA
- -53.6%
- EBIT
- -42.3%
- Net income
- -51.3%
- EPS
- -35.5%
- Free cash flow
- +1.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026